» Articles » PMID: 35105408

Poor Outcomes in Both Infection and Colonization with Carbapenem-resistant Enterobacterales

Abstract

Objectives: To describe the epidemiology of patients with nonintestinal carbapenem-resistant Enterobacterales (CRE) colonization and to compare clinical outcomes of these patients to those with CRE infection.

Design: A secondary analysis of Consortium on Resistance Against Carbapenems in and other Enterobacteriaceae 2 (CRACKLE-2), a prospective observational cohort.

Setting: A total of 49 US short-term acute-care hospitals.

Patients: Patients hospitalized with CRE isolated from clinical cultures, April, 30, 2016, through August 31, 2017.

Methods: We described characteristics of patients in CRACKLE-2 with nonintestinal CRE colonization and assessed the impact of site of colonization on clinical outcomes. We then compared outcomes of patients defined as having nonintestinal CRE colonization to all those defined as having infection. The primary outcome was a desirability of outcome ranking (DOOR) at 30 days. Secondary outcomes were 30-day mortality and 90-day readmission.

Results: Of 547 patients with nonintestinal CRE colonization, 275 (50%) were from the urinary tract, 201 (37%) were from the respiratory tract, and 71 (13%) were from a wound. Patients with urinary tract colonization were more likely to have a more desirable clinical outcome at 30 days than those with respiratory tract colonization, with a DOOR probability of better outcome of 61% (95% confidence interval [CI], 53%-71%). When compared to 255 patients with CRE infection, patients with CRE colonization had a similar overall clinical outcome, as well as 30-day mortality and 90-day readmission rates when analyzed in aggregate or by culture site. Sensitivity analyses demonstrated similar results using different definitions of infection.

Conclusions: Patients with nonintestinal CRE colonization had outcomes similar to those with CRE infection. Clinical outcomes may be influenced more by culture site than classification as "colonized" or "infected."

Citing Articles

Molecular epidemiology and patient outcome of carbapenem-resistant and in Japan: a multicenter study from MultiDrug-Resistant organisms clinical research network.

Saito S, Sakurai A, Matsumura Y, Uemura K, Hase R, Kato H JAC Antimicrob Resist. 2025; 7(2):dlaf027.

PMID: 40051884 PMC: 11882498. DOI: 10.1093/jacamr/dlaf027.


Carbapenem-resistant Klebsiella pneumoniae: Risk Factors for Isolation Among Hospitalized Patients.

Kobaidze K, Jacob J, Leong T, Flanders W Brown J Hosp Med. 2025; 2(1):57568.

PMID: 40046553 PMC: 11878813. DOI: 10.56305/001c.57568.


The Next Generation: Mentoring and Diversity in the Antibacterial Resistance Leadership Group.

Harris A, Souli M, Pettigrew M Clin Infect Dis. 2023; 77(Suppl 4):S331-S335.

PMID: 37843116 PMC: 10578050. DOI: 10.1093/cid/ciad532.


Risk Factors and Clinical Impact of Carbapenem-Resistant Coinfections Among Hospitalized Patients with Infection.

Lee C, Chiu C, Lee J, Tsai P, Ko W, Hung Y Infect Drug Resist. 2022; 15:6287-6295.

PMID: 36337933 PMC: 9635385. DOI: 10.2147/IDR.S386309.


Study on the Detection and Infection Distribution of Multidrug-Resistant Organisms in Different Specimens.

Li Z, Zhang Y, Zhang W, Zhang Y, Zhou S, Chen W Infect Drug Resist. 2022; 15:5945-5952.

PMID: 36247737 PMC: 9560865. DOI: 10.2147/IDR.S375682.